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ABSTRACT 
Dysregulated alternative splicing plays a prominent role in all hallmarks of cancer. The splice 
factor kinase SRPK1 drives the activity of oncogenic splice factors such as SRSF1. SRSF1 in turn 
promotes the expression of splice isoforms that favour tumour growth, including 
proangiogenic VEGF. Knockdown (with siRNA) or chemical inhibition (using SPHINX) of SRPK1 
in K562 leukemia and PC3 prostate cancer cell lines reduced cell proliferation, invasion and 
migration. In glomerular podocytes, the Wilms tumour suppressor zinc-finger transcription 
factor WT1 represses SRPK1 transcription. Here we show that in cancer cells WT1 activates 
SRPK1 transcription, unless a canonical WT1 binding site adjacent to the transcription start 
site is mutated. The ability of WT1 to activate SRPK1 transcription was reversed by the 
transcriptional corepressor BASP1. Both WT1 and BASP1 co-precipitated with the SRPK1 
promoter, and BASP1 significantly increased the expression of the antiangiogenic VEGF165b 
splice isoform. We propose that by upregulating SRPK1 transcription WT1 can direct an 







































































Up to 94% of human multi-exon genes are alternatively spliced [41], enabling genes to express 
multiple splice isoforms, often exhibiting antagonistic properties. Not surprisingly, alternative 
splicing affects genes involved in all hallmarks of cancer and the factors that regulate 
alternative splicing are often deregulated [32]. There is increasing interest in understanding 
how aberrant alternative splicing contributes to cancer hallmarks, and to explore ways in 
which the manipulation of splicing could be used therapeutically [6]. 
Of particular interest to cancer biologists is the alternative splicing of VEGFA, encoding the 
widely studied vascular endothelial growth factor (VEGF). The VEGFA transcript is comprised 
of eight exons and the alternative splicing of exons 5-7 results in the expression of splice 
isoforms with different activities and bioavailabilities [42]. An additional splice isoform was 
discovered arising from an alternative, distal 3′ splice site in terminal exon 8 which results in 
six different amino-acids at the C-terminus. This new splice isoform was called VEGFxxxb 
(where xxx represents the total number of amino-acids in the isoform). VEGFxxxb isoforms are 
antiangiogenic and downregulated in cancer, suggesting a therapeutic benefit in modifying 
their expression [21,42]. We previously demonstrated that the oncogenic splice factor SRSF1 
promotes proangiogenic VEGF splice isoform expression by enhancing the use of the proximal 
3′ splice site in exon 8 [30,31]. There are physiological contexts in which antiangiogenic 
VEGFxxxb expression is more appropriate, for example in glomerular podocytes. To gain 
further insights into regulation, we previously investigated the cause of severely reduced 
VEGFxxxb expression in podocytes derived from children with Denys-Drash Syndrome (DDS) in 
which the WT1 (Wilms’ tumour suppressor) zinc-finger transcription factor is mutated with 




































































serine-arginine splice factor protein kinase (SRPK1) was abnormally high. In wildtype 
podocytes WT1 acts as a transcriptional repressor of SRPK1 and binds to a GC-rich sequence 
proximal to the transcription start site. However, in DDS, SRPK1 is derepressed; as a result, 
high SRPK1 levels lead to increased phosphorylation, nuclear localisation and activity of SRSF1 
resulting in higher expression of proangiogenic VEGF [1].  
SRSF1 was the first splice factor to be described as a proto-oncogene [2,20]. The splice factor 
kinase SRPK1 is now also considered to exhibit oncogenic properties. SRPK1 is upregulated in 
prostate cancer, correlating with increased invasion and angiogenesis [8]. High SRPK1 
expression is a poor prognostic indicator in colorectal cancer [44]. SRPK1 promotes tumour 
cell migration and metastasis [38] and inhibits apoptosis in breast cancer [23]. SRPK1 targeting 
with kinase inhibitors is a potential novel antiangiogenic strategy in melanoma [13] and 
prostate cancer [27].  
WT1 can both activate and repress target genes depending on the presence of cofactors 
[34,36]. Brain acid soluble protein 1 (BASP1) promotes WT1’s transcriptional repression 
activity through PIP2-dependent recruitment of histone deacetylase [9,35]. BASP1 expression 
is evident in developing nephron structures in the embryonic kidney and in adult podocytes. 
In a conditionally-immortalised human podocyte cell line model that can differentiate in vitro, 
WT1 and BASP1 co-precipitate with the podocyte-specific PODXL gene promoter. PODXL 
encodes podocalyxin, a podocyte-specific cell adhesion sialoglycoprotein. Upon 
differentiation, the association of BASP1 with the PODXL promoter is reduced, allowing WT1 
to activate its transcription [16]. The myelogenous leukemia cell line K562 expresses WT1, but 
not BASP1. When BASP1 is expressed in genetically engineered K562 cells, WT1 can induce 
differentiation to a neuronal-like phenotype, characterised by an arborized morphology and 




































































The proteins work together in other contexts: murine Wt1 and Basp1 repress Wnt4 in 
epicardial cells [12] and maintain the differentiated state of human taste receptor cells [14].  
Despite WT1’s initial characterisation as a classic tumour suppressor gene, it is increasingly 
evident that WT1 can also act as an oncogene in the context of several cancers including 
leukemia [24,43], breast cancer [45] and neuroblastoma [33]. WT1 promotes tumour 
angiogenesis and metastasis, and inhibits the anti-tumoral immune response [39]. At a 
molecular level WT1 can exert its oncogenic effects by activating transcription of the MYC 
proto-oncogene [17]; by repressing CDH1 (encoding E-cadherin) transcription [7]; and by 
interacting with the mitochondrial protease HtrA, promoting antiapoptotic activity [11]. 
Given the importance of dysregulated alternative splicing in cancer, we reasoned that WT1 
might also exert its oncogenic effects through the regulation of transcription of the oncogenic 
splice factor kinase gene SRPK1. We hypothesized that in leukemia and prostate cancer cells 
WT1 activates SRPK1 transcription in the absence of BASP1. 
 
2. Materials and Methods 
2.1 Cell culture and SPHINX treatments 
The K562 cell line (ATCC CRL-3344) was cultured using RPMI-1640 culture medium with L-
glutamine (Sigma). V-K562 (stably transfected with empty vector (EV) pcDNA3) and B-K562 
cells (stably transfected with BASP1-expressing pcDNA3, prepared in Prof. Stefan Roberts’ 
laboratory as previously described [36]) were grown in similar conditions with 2mg/ml G418 
(Sigma) to maintain selection for BASP1-expressing cells. Human prostate cancer cells PC3 
(ATCC CRL-1435) were cultured in DMEM (Sigma). Both cell lines are guaranteed as authentic 




































































bovine serum (FBS) and 0.1mg/ml penicillin/streptomycin (Sigma). For SRPK1 inhibition, 
K562-derived or PC3 cell lines, up to 2x106 cells, were treated with 5-methyl-N-[2-(morpholin-
4-yl)-5-(tri-fluoromethyl) phenyl] furan-2-carboxamide (SPHINX), purchased from Enamine 
(Ukraine). 
 
2.2 Cloning and the Dual-Luciferase Renilla (DLR) assays 
The SRPK1 promoter was cloned into a pGL3 luciferase vector (Promega) for in vitro 
transcription assays [1]. The WT1 binding site (GGGGCGGGGG) located adjacent to the 
transcription start site was mutated to GAATTCAAAA. Transcription was measured using the 
Dual-Luciferase Renilla (DLR) assay (Promega). PC3, wildtype V-K562 and B-K562 cells were 
seeded in 24 well plates at 5 x 104 cells per well, 24h before transfection. Cells were 
transfected with transfection reagent (Lipofectamine 2000, ThermoFisher Scientific)  using 
2μg plasmid/100μl) using equal amounts (0.8g for 24 well, 1.6g for 12 well and 4.0g per 
6 well plates) of Renilla-expressing plasmid and SRPK1 promoter: luciferase pGL3 constructs, 
wild-type and mutant. For experiments involving BASP1, two different concentrations (0.5 
and 1.5µg) of BASP1-expressing plasmid were used (pcDNA3) [9]. 
 
2.3 SiRNA-mediated knockdown of WT1 and SRPK1   
SiRNAs targeting WT1, SRPK1 and a negative control (firefly luciferase GL2) were as described 
[4,10] (Eurofins Genomics). Cells were transfected at 80% confluence 24hrs after seeding with 
10nM, 50nM or 100nM final siRNA concentrations using the Lipofectamine RNAiMAX 
transfection reagent (ThermoFisher Scientific) and cells were harvested 48h post-
transfection. In the DLR assays, cells were co-transfected with 100nM siRNA and 2.5g pGL3 






































































2.4 Western Blotting 
Cells lysates were prepared using RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% (v/v) 
Triton X-100, 0.1% (w/v) sodium deoxycholate, 0.1% (w/v) SDS and 140 mM NaCl) 
supplemented with protease inhibitor tablets (ThermoFisher Scientific). Equal protein 
samples, 20 g protein, were separated on 10% (v/v) SDS polyacrylamide gels and transferred 
to PVDF membranes (Sigma) which were blocked and probed overnight at 4 °C with primary 
antibodies: anti- WT1 (ab89901, Abcam; 1:1000), anti-β-actin (ab8226, Abcam; 1:5000), anti-
BASP1 (ab214322, Abcam; 1:1000), anti-SRPK1 (EE13, Santa Cruz; 1:1000), anti-VEGF (AF-293-
NA, R&D Systems; 1:1000), anti VEGFxxxb (MAB3045-100, R&D Systems; 1:1000). Membranes 
were incubated in HRP-linked anti-rabbit or anti-mouse IgG secondary antibody (Cell 
Signalling; 1:1500) for 1h at room temperature. Membranes were incubated in Luminata 
Forte Western HRP substrate (Millipore) for chemiluminescent detection prior to image 
acquisition using a Li-Cor Odyssey imaging system. When required, western blots were 
stripped in order to re-probe them with the β-actin loading control antibody. Band densities 
were exported and analysed using GraphPad Prism software. Statistical differences between 
treatments groups were compared using ANOVAs and t-tests.  
 
2.5 Chromatin immunoprecipitation assays 
Chromatin immunoprecipitation (ChIP) was performed on PC3, K562 and B-K562 cells using 
the Imprint Chromatin Immunoprecipitation Kit (Sigma). Cells were incubated for 10 minutes 
with 1% (w/v) formaldehyde at room temperature to cross-link DNA and protein. Cells were 




































































protein mixture was incubated with 3μg of WT1 and BASP1 antibodies or with 1μg of RNA 
Polymerase II antibody (positive control) or 1μg non-specific mouse IgG (negative control). 
DNA was eluted (GeneElute columns, Sigma) and used in PCR to detect SRPK1 and GAPDH 
promoter sequences that were immunoprecipitated. PCR was performed at 95°C initially for 
2 minutes followed by up to 35 cycles: 95°C for 1 minute, annealing for 1 minute at 55°C and 
extension at 72°C for 1 minute followed by a final elongation at 72°C for 5 minutes. The 
identity of the amplicons was verified by sequencing (Eurofins Genomics). 
 
2.6 MTT assay for cell proliferation and viability 
1x105 cells per well were seeded in 96-well plates. Following treatments and transfections, 
media was removed and a mixture of serum-free media and MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) solution (ab211091, Abcam) was added to each well. 
After incubation at 37°C for 3 h, MTT solvent was added and absorbance at 590 nm was 
measured. Cell proliferation was determined using the corrected absorbance value (test 
sample - culture medium background) of the formazan precipitate which is proportional to 
cell number. Cell viability was calculated: cell viability % = (control - absorbance of treatment 
wells) / absorbance of control well × 100. 
 
2.7 Transwell cell migration and invasion assays 
For cell migration, PC3 cells were re-suspended in serum-free medium and transferred to the 
top chamber of transwell inserts. For the invasion assay, inserts were pre-coated with 50l of 
Matrigel (Corning) and allowed to solidify overnight. Complete medium containing 10% FBS 
was added to the lower chamber of the 24-well plate and cells were allowed to migrate for 




































































paraformaldehyde and stained with 0.2% (w/v) crystal violet in 2% methanol. To quantify the 
migration of cells, 0.1% (w/v) SDS in PBS was added to the lower chambers and absorbance 




3.1 WT1 activates SRPK1 transcription in K562 leukemia and PC3 prostate cancer cell lines 
We previously showed that WT1 represses transcription of the splice factor kinase gene 
SRPK1 in conditionally-immortalised wild-type glomerular podocytes. This activity is lost in 
DDS podocytes in which several, independent zinc-finger domain mutations impair the ability 
of WT1 to bind to its DNA targets [1]. We fused the SRPK1 promoter to a luciferase reporter, 
both wild-type and with a mutation in the WT1 binding site (GGGGCGGGGG to GAATTCAAAA) 
[1]. We transfected these reporters into two independent, well-characterised WT1-
expressing cancer cell lines; PC3, derived from a prostate cancer bone metastasis, and K562, 
derived from chronic myelogenous leukemia [9,19]. In both cell lines the wild-type SRPK1 
promoter was clearly active, whereas the mutant SRPK1 promoter was not (Fig. 1). Co-
transfection of an siRNA directed against WT1 strongly reduced the activity of the wild-type 
SRPK1 promoter. We also measured the effect of siRNA-mediated WT1 knockdown on the 
expression of endogenous SRPK1 in K652 (Fig. 2A,B) and PC3 cells (Fig. 2C,D). In both cell lines 
the knockdown of WT1 resulted in a significant reduction in endogenous SRPK1 protein levels.  
To confirm the oncogenic properties of SRPK1, we transfected both cell lines with siRNA 
directed against SRPK1 and treated cells with SPHINX, a 3-(trifluoromethyl)anilide scaffold 




































































SPHINX) significantly reduced cell proliferation and viability in both cell lines (Fig. 3). We 
performed transwell assays with adherent PC3 cells, and observed that SPHINX treatment 
reduced cell migration and invasion, confirming the oncogenic properties of SRPK1.  
We previously co-precipitated WT1 with the endogenous SRPK1 promoter using nuclear 
extracts from glomerular podocytes [1]. We tested whether WT1 similarly interacts with the 
SRPK1 promoter in K562 and PC3 cells using ChIP. WT1 co-precipitated with the SRPK1 
promoter in both K562 (Fig. 4A,B) and PC3 (Fig. 4C,D) cells. The sequence amplified from the 
ChIP comprises the WT1 binding and transcription start sites and its identity was confirmed 
by sequencing (Fig. 4E). A positive control (antibody against RNA polymerase II) and a negative 
control (mouse IgG) confirmed the specificity of the pull-down. As a further control, the 
GAPDH promoter co-precipitated with the RNA polymerase II, but not with the WT1 antibody.  
Taken together these experiments suggest that in both leukemia and prostate cancer cells, 
WT1 interacts with the SRPK1 promoter through its cognate WT1 binding site located 
proximal to the transcription start site. However instead of repressing (as in glomerular 
podocytes), WT1 activates SRPK1 transcription in these two cancer cell lines. Given that the 
transcriptional corepressor BASP1 is expressed in glomerular podocytes [9], we next 
examined BASP1’s effect on the ability of WT1 to activate SRPK1 transcription. 
 
3.2 In the presence of BASP1, WT1 fails to activate SRPK1 transcription in K562 cells 
K562 cells do not express detectable levels of BASP1. A K562 cell line subclone that stably 
expresses BASP1, called B-K562 is available [15]. We transfected the SRPK1 
promoter:luciferase reporter into both K562 and B-K562 cells and observed reduced SRPK1 
promoter activity in B-K562 cells (Fig. 5A). To confirm the effect of BASP1 on SRPK1 expression 




































































with a BASP1-expressing plasmid. Co-transfection of the SRPK1 promoter:luciferase construct 
with empty vector (EV) had no effect, whereas the BASP1-expressing plasmid significantly 
reduced activity (Fig. 5B), confirming the observation in B-K562 cells (Fig. 5A). Next we 
examined the expression of endogenous SRPK1 in K562 and B-K562 cells. As expected, BASP1 
was undetectable in parental K562 cells, but highly expressed in B-K562 cells (Fig. 5C,D). 
SRPK1 levels were significantly reduced in B-K562 cells. We also observed a reduction in 
endogenous WT1 (Fig. 5C,D). Next, we performed ChIP analysis on B-K562 cells, and 
confirmed that BASP1, like WT1, associates with the SRPK1 promoter (Fig. 5E,F).  
 
3.3 BASP1 increases the expression of antiangiogenic VEGF splice isoforms in PC3 cells 
Having established that WT1 activates the transcription of SRPK1 in cancer cells in the absence 
of BASP1, we next examined a previously characterised downstream effect of SRPK1 
transcriptional regulation by WT1. BASP1 is expressed in glomerular podocytes in which WT1 
represses SRPK1 [1,9]. Lower SRPK1 expression in wild-type podocytes results in reduced 
phosphorylation of SRSF1, therefore less active nuclear SRSF1. This favours the use of the 
distal alternative 3′ splice site in VEGF exon 8 resulting in higher expression of the 
antiangiogenic VEGFxxxb splice isoform. We previously showed that the inhibition of SRPK1 
with SPHINX in PC3 cells in orthotopic mouse xenografts drastically reduces tumour growth, 
correlating with increased expression of antiangiogenic VEGFxxxb [27]. The overexpression of 
proangiogenic VEGF in PC3 cells in which SRPK1 is stably knocked down restores xenograft 
growth [27]. We therefore reasoned that increased levels of BASP1 in PC3 cells would result 
in a similar shift in VEGF alternative splicing. Firstly we confirmed that the inhibition of SRPK1 
in PC3 cells with SPHINX significantly increased expression of the antiangiogenic splice isoform 




































































into PC3 cells. The expression of BASP1 in PC3 cells mirrored the effect of SRPK1 inhibition by 
SPHINX, increasing the expression of VEGF165b relative to total VEGF165 (Fig. 6B,C).  
 
4. Discussion 
We had previously shown that WT1 acts as a transcriptional repressor of SRPK1 in glomerular 
podocytes in which the corepressor BASP1 is expressed [1,9]. WT1’s ability to activate or 
repress SRPK1 transcription depends on the presence of specific cofactors such as BASP1 with 
which it physically interacts [9,16]. We propose a model for the regulation of SRPK1 
transcription by WT1 (Figure 7). WT1 binds to its cognate GC-rich binding site proximal to the 
transcription start site. In proliferating cells (and cancer cells), in the absence of BASP1, WT1 
recruits transcriptional co-activators (CBP and associated histone acetyl transferase activity). 
In cells that are differentiated and non-proliferative, such as glomerular podocytes, BASP1 is 
expressed. This converts WT1 to a transcriptional repressor by recruiting histone deacetylase 
in the presence of the co-factor PI4,5P2.The ability of transcription factors to activate and 
repress target genes is well established and WT1 is not unusual in having this dual ability [22].  
WT1 both activates and represses Wnt4 transcription through a chromatin structure 
switching mechanism [12].  
We also observed a reduction in WT1 levels in B-K562 cells. WT1’s ability to autoregulate its 
own expression has previously been reported in K562 cells [3,25]. Thus the expression of 
BASP1 in B-K562 cells also reduces WT1 expression, contributing to the downregulation of 
SRPK1.  
WT1 is a highly multifunctional protein and its zinc-fingers can interact with both DNA and 




































































we have previously observed that WT1 is present in mRNP complexes in K562 cells [28]. 
Bharathavikru and colleagues identified RNA targets of WT1 in ES cells [5]. They showed that 
WT1 binds preferentially to the 3′ untranslated regions of developmentally expressed mRNAs 
contributing to the regulation of mRNA turnover. Whether or not WT1 also regulates SRPK1 
expression post-transcriptionally remains to be investigated.  
A recent study by Wagner and colleagues [40] examined the expression of Wt1, Srpk1 and 
Srsf1 in tumours compared to normal murine lung endothelium. All were highly expressed in 
tumour endothelium compared to healthy tissue, together with proangiogenic VEGF splice 
isoforms. This pattern correlated with a stronger nuclear localisation of the splice factor 
SRSF1, consistent with the effects of high SRPK1 activity, and similar to what had previously 
been described in DDS podocytes in which WT1 is mutated and SRPK1 de-repressed [1]. The 
authors then used an inducible conditional vessel-specific knockout of Wt1, and observed a 
drop in the expression of Srpk1, and a resulting increase in the expression of antiangiogenic 
VEGF. They also showed that Wt1 binds to and activates the Srsf1 and Srpk1 promoters in 
murine endothelial cells [40], consistent with our findings. We have not examined the effect 
of WT1 on the transcription of SRSF1 in PC3 and K562 cells within the scope of the present 
study. It is reasonable to speculate that WT1 upregulates the transcription of SRSF1, and 
potentially of other oncogenic splice factors and splice factor kinases in cancer as well as 
SRPK1. 
WT1’s role in cancer, either as an oncogene or tumour suppressor, is now well established 
[24,43]. Here we provide further evidence that confirms the critical role of BASP1 in 
modulating WT1’s oncogenic activity. There is increasing evidence that BASP1 has a 
prominent role in oncogenic processes. BASP1 can counteract the oncogenic role of MYC by 




































































receptor  and enhances the antitumourigenic effects of tamoxifen, and its expression is 
associated with better prognosis in breast cancer [26]. In acute myeloid leukemia, the 
oncogenic AML1-ETO fusion protein resulting from the t(8;21) translocation recruits DNA 
methyltransferase 3a (DNMT3a) to the BASP1 promoter, causing its silencing. Re-expression 
of BASP1 reduces the proliferative capacity of the leukemic cells [47]. Consistent with its 
tumour suppressor properties in pancreatic cancer tissue, a proteomic screen identified 
BASP1 as a potential prognostic biomarker. Immunohistochemical analysis suggested that 
BASP1 expression is associated with better survival and favourable response to adjuvant 
chemotherapy [46].  
 
5. Conclusion 
In summary, we have shown that WT1 activates SRPK1 transcription in two independent 
cancer cell lines, K562 and PC3; and that WT1’s ability to activate SRPK1 transcription is 
prevented by the transcriptional corepressor BASP1. The ability of WT1 to activate SRPK1 
transcription is likely to contribute to oncogenic processes in many types of cancer. We 
suggest that through the activation of SRPK1 transcription, WT1 stimulates the activity of 
oncogenic splice factors such as SRSF1, altering the alternative splicing landscape to favour 
tumour growth including the expression of proangiogenic VEGF. These findings add a novel 
dimension to WT1's oncogenic functions. We suggest that there are opportunities to develop 
novel cancer therapies focused on blocking both WT1 activity and that of its downstream 
target, the splice factor kinase gene SRPK1. 
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Supplementary information is available for this paper online. 
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Fig. 1. The SRPK1 promoter fused to a luciferase reporter is active in WT1-expressing (A) PC3 
and (B) K562 cells (Dual Luciferase-Renilla (DLR) assay). A mutated SRPK1 promoter in which 
the WT1 binding site was removed (mutSRPK1) is not active. The knockdown of WT1 with 
siRNA reduces the activity of the wild-type SRPK1 promoter in both cell lines. The control 
siRNA (Ctrl) is the firefly luciferase GL2. RLU, relative luciferase units normalised to Renilla. 
Data are means ± S.E. *** p<0.01; ** p<0.001, one-way ANOVA (n=3). SiRNA-mediated WT1 
knock-down in the DLR experiments was verified by western blotting in PC3 (C) and K562 (D) 
cell lines; 20g total protein was loaded in each lane. 
 
Fig. 2. Effect of WT1 knockdown on endogenous SRPK1 expression in K652 and PC3 cells. 
SiRNA directed against WT1 reduces the expression of WT1 and SRPK1. (A) Western blot of 
transfected K562 cells, quantified in (B) relative to -actin; (C) and (D) in PC3 cells; 20g total 
protein was loaded in each lane. **** p<0.0001, *** p=0.0002 ** p<0.01, * p<0.05, two-way 
ANOVA (n=3).  
 
Fig. 3. Effect of SRPK1 knockdown and inhibition on cell proliferation, migration and invasion. 
The MTT assay was used to analyse the effect of SRPK1 knockdown via both 100nM siRNA 
(for 48hrs) and SRPK1 inhibition with SPHINX (for 72hrs) on cellular proliferation (A,C) and 
viability (B,D) in K562 and PC3 cells. Data represent mean ± S.E. **** p<0.0001, *** p<0.001, 




































































cell migration and invasion. PC3 cells were treated with 10M SPHINX for 48hrs and examined 
for cell migration (E) and invasion (F) in a transwell assay. ** p=0.0089, * p=0.0211, unpaired 
t test (n=3). The siRNA-mediated SRPK1 knock-down was verified by western blot in K562 (G) 
and PC3 (H) cells; 20g total protein was loaded in each lane. 
 
Fig. 4. WT1 co-immunoprecipitates with the SRPK1 but not the GAPDH promoter in (A) K562 
and (C) PC3 cells, respectively quantified in (B) and (D). RNA polymerase II (positive control) 
and mouse IgG (negative control) are included. Data are expressed as means ± S.E. **** 
p<0.0001, one-way ANOVA (n=3). (E) Verification of SRPK1 ChIP. The PCR product amplified in the 
WT1 and BASP1 ChIP experiments was sequenced (Eurofins Genomics). The forward primer lies just 
upstream of the transcription start site and the canonical WT1 binding site (in bold); the reverse 
primer is in the SRPK1 5’UTR. Partial SRPK1 mRNA (accession NM_003137) and SRPK1 promoter 
sequences (Eukaryotic Promoter Database, https://epd.epfl.ch/) are shown. The transcription start 
site (+1) is indicated. 
 
 
Fig. 5. The presence of BASP1 prevents SRPK1 transcription activation by WT1. (A) The 
wildtype SRPK1 promoter is active in K562 cells, but significantly less active in B-K562 cells 
which overexpress BASP1. (B) Transfection of a BASP1-expressing plasmid reduces the activity 
of the SRPK1 promoter, as per the removal of the WT1 binding site (mutSRPK1). (C) Western 
blot comparing the expression of BASP1, SRPK1, and WT1 in K562 cells and B-K562 cells that 
overexpress BASP1, quantified in (D). 20g total protein was loaded per lane; the bar-graph 
represents three independent experiments. BASP1 co-immunoprecipitates with the SRPK1 




































































control) and mouse IgG (negative control) are included. Data expressed as means ± S.E. For 
(a) and (b): **** p<0.0001, *** p<0.001, one-way ANOVA (n=3). For (d) and (f): **** 
p<0.0001, * p<0.05, two-way ANOVA (n=3). 
 
Fig. 6. Effect of SRPK1 inhibition and BASP1 expression on the expression of antiangiogenic 
VEGF165b. (A) PC3 cells were treated for 48 h  with 10M of the SRPK1 inhibitor SPHINX. 
Western blot showing the expression of VEGF165b relative to total VEGF165. 20g total protein 
was loaded per lane.  (B) BASP1-expressing plasmid was transiently transfected into PC3 cells; 
elevated BASP1 expression was confirmed by western blotting relative to -actin. (C) The 
effect of BASP1 on VEGF165b expression in PC3 cells transfected with BASP1-expressing 
plasmid. 20g total protein was loaded in each lane. ** p<0.01, * p<0.05, unpaired t test 
(n=3). 
 
Fig. 7. Proposed model for the regulation of SRPK1 transcription by WT1. (A) WT1 binds to a 
GC-rich target sequence adjacent to the transcription start site and activates SRPK1 
transcription (e.g. in cancer cells) by recruiting co-factors that open up chromatin (p300-CBP) 
together with histone acetyltransferases (HAT).(B) WT1 represses (e.g. in glomerular 
podocytes) SRPK1 transcription in the presence of the transcriptional co-repressor BASP1, its 
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